Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-1/PD-L1 and immunotherapy for pancreatic cancer
Mengyu Feng, Guangbing Xiong, Zhe Cao, et al.
Cancer Letters (2017) Vol. 407, pp. 57-65
Closed Access | Times Cited: 284

Showing 26-50 of 284 citing articles:

Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation
Yingying Shen, Chaojie Lu, Zhengbo Song, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 60
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Lingyue Liu, Xing Huang, Fukang Shi, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 59
Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice
Heng Zhou, Chen Tu, Pengfei Yang, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 57
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Célia Jacoberger-Foissac, Isabelle Cousineau, Yacine Barèche, et al.
Cancer Immunology Research (2022) Vol. 11, Iss. 1, pp. 56-71
Open Access | Times Cited: 42
SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma
Wei Wu, Zhenghao Zhang, Doudou Jing, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 6
Open Access | Times Cited: 41
Promising Nanomedicines of Shikonin for Cancer Therapy
Chunmei Yan, Qiuxia Li, Qiang Sun, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 1195-1218
Open Access | Times Cited: 37
Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing
Kai Chen, Qi Wang, Xinxin Liu, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 25
Engineered Cell Membrane-Camouflaged Nanomaterials for Biomedical Applications
Xiaoxuan Guan, Simin Xing, Yang Liu
Nanomaterials (2024) Vol. 14, Iss. 5, pp. 413-413
Open Access | Times Cited: 10
It’s about TIME – Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma
Christin Knickmeier, Gaetan Aime Noubissi Nzeteu, Bernhard F. Gibbs, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
Weibin Xie, Lihui Liang, Kai-Ge Wu, et al.
Cellular Physiology and Biochemistry (2018) Vol. 46, Iss. 2, pp. 654-663
Open Access | Times Cited: 73
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Ombretta Melaiu, Valeria Lucarini, Roberto Giovannoni, et al.
Seminars in Cancer Biology (2020) Vol. 79, pp. 18-43
Open Access | Times Cited: 60
HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins
Reza Beheshti Zavareh, Stephan H. Spangenberg, Ashley Woods, et al.
Cell chemical biology (2020) Vol. 28, Iss. 2, pp. 158-168.e5
Closed Access | Times Cited: 58
An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives
Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, et al.
Oral Diseases (2019) Vol. 26, Iss. 3, pp. 511-526
Closed Access | Times Cited: 57
Dilemma and Challenge of Immunotherapy for Pancreatic Cancer
Jia Wu, Jianting Cai
Digestive Diseases and Sciences (2020) Vol. 66, Iss. 2, pp. 359-368
Closed Access | Times Cited: 57
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
Yu Pan, Qinglin Fei, Ping Xiong, et al.
OncoImmunology (2019) Vol. 8, Iss. 5, pp. e1581529-e1581529
Open Access | Times Cited: 55
Recent advances on microneedle arrays-mediated technology in cancer diagnosis and therapy
Vahid Alimardani, Samira Sadat Abolmaali, Ali Mohammad Tamaddon, et al.
Drug Delivery and Translational Research (2020) Vol. 11, Iss. 3, pp. 788-816
Closed Access | Times Cited: 53
Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy
Ju Huang, Liang Zhang, Weichen Zhou, et al.
Biomaterials (2021) Vol. 274, pp. 120856-120856
Closed Access | Times Cited: 45
Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
Hongbo Li, Zihan Yang, Qingqu Guo
Cell Communication and Signaling (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 44
Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of Lung Cancer Cells Mediated by PD-L1
Jianru Yang, Yang Jia, Bing Wang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 43
Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer
Heather Nesbitt, Keiran Logan, Keith Thomas, et al.
Cancer Letters (2021) Vol. 517, pp. 88-95
Open Access | Times Cited: 43
SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer
Tianjiao Li, Kaizhou Jin, Hao Li, et al.
Cancer Letters (2022) Vol. 530, pp. 142-155
Closed Access | Times Cited: 34
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
Adam Nelson, Simon Gebremeskel, Brian D. Lichty, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e003923-e003923
Open Access | Times Cited: 32
Targeted mechanical forces enhance the effects of tumor immunotherapy by regulating immune cells in the tumor microenvironment
Pengfei Zhu, Hongrui Lu, Mingxing Wang, et al.
Cancer Biology and Medicine (2023) Vol. 20, Iss. 1, pp. 44-55
Open Access | Times Cited: 21
Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
Tarak Chouari, Francesca Soraya La Costa, Nabeel Merali, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4265-4265
Open Access | Times Cited: 21
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
Ting-Lin Yang, Wenhui Li, Tao Huang, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 526-526
Open Access | Times Cited: 18

Scroll to top